We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Avacta Group Plc | LSE:AVCT | London | Ordinary Share | GB00BYYW9G87 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-1.25 | -2.55% | 47.75 | 47.50 | 48.00 | 48.75 | 47.50 | 48.75 | 1,273,203 | 09:51:38 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 10.06M | -39.19M | -0.1382 | -3.46 | 135.43M |
TIDMAVCT
Avacta Group PLC
11 January 2017
11(th) January 2017
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Avacta to present at the London Growth and Innovation Forum
Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and research reagents, is pleased to announce that its Chief Executive, Alastair Smith, will be presenting at the London Growth and Innovation Forum on 31(st) January 2017 at the Business Design Centre, London.
The Growth & Innovation Forum is a one-day investor exhibition showcasing innovative technology led companies.
Avacta Group's management team will be at stand 18 during the day and Chief Executive Alastair Smith will be presenting at 1500 in the Babbage room.
For more information, including registration details, please visit:
http://www.sharesmagazine.co.uk/events/event/GIF2017
ENDS
Notes to Editors
For further information from Avacta Group plc, please contact:
Avacta Group plc Tel: +44 (0) 844 414 0452 Alastair Smith, Chief Executive www.avacta.com Officer Tony Gardiner, Chief Financial Officer finnCap Ltd Tel: +44 (0) 207 220 0500 Geoff Nash / Giles Rolls www.finncap.com - Nominated Adviser Tim Redfern / Alice Lane - Corporate Broking Tel: +44 (0) 203 705 9318 Tel: +44 (0) 203 705 9217 WG Partners www.wgpartners.co.uk David Wilson Nigel Barnes Claes Spang Zyme Communications (Trade Tel: +44 (0)7787 502 947 and Regional Media) katie.odgaard@zymecommunications.com Katie Odgaard Tel: +44 (0) 203 727 1000 FTI Consulting (Financial avacta@fticonsulting.com Media and IR) Simon Conway / Natalie Garland-Collins
About Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer(R) technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.
Antibodies dominate markets worth in excess of $50bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is also commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALFFSLLFIILID
(END) Dow Jones Newswires
January 11, 2017 02:00 ET (07:00 GMT)
1 Year Avacta Chart |
1 Month Avacta Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions